MGN-9103 is an antagomiR designed against miR-208, a cardiac-specific miRNA with known benefits for cardiac function and has a therapeutic potential in improving systemic insulin sensitivity and glucose tolerance that contribute to MetS. The gene discussed is INS; the disease is metabolic syndrome.